EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma

Zhenyuan Zhao, Kun Ju iD, Jiajun Lv, Zidong Lu, Lei Luo iD

Mediators of Inflammation · 2026-01 · 2026 (1)

DOI: 10.1155/mi/8383379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 24.04.2026. Verfasst von Zhenyuan Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, 266071, Qingdao, China, qdu.edu.cn. Hauptthemen laut MEDLINE: Colonic Neoplasms, Adenocarcinoma. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colon adenocarcinoma (COAD) exhibits marked molecular heterogeneity that limits accurate prognostic prediction and therapeutic stratification. Parthanatos, a poly (ADP‐ribose) polymerase‐1 (PARP1)‐dependent form of regulated cell death, has been implicated in tumor biology, yet its relevance in COAD remains poorly understood. In this study, we systematically characterized parthanatos‐associated genes (PAGs) using integrated transcriptomic analyses from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts. Distinct parthanatos‐related molecular subtypes with significantly different clinical outcomes and immune landscapes were identified. A parthanatos‐based prognostic scoring system was constructed using machine learning algorithms and validated in an independent cohort, demonstrating robust predictive performance and independent prognostic value. High PAG scores were associated with advanced disease stage, altered immune infiltration, increased tumor mutation burden (TMB), and differential sensitivity to chemotherapy and predicted immunotherapy response. Single‐cell RNA sequencing further revealed broad cellular expression of PAG, while preliminary in vitro experiments suggested that solute carrier family 2 member 3 (SLC2A3), the most prominent risk gene in the prognostic model, may promote COAD cell proliferation and invasion, although these findings require validation in additional models. Collectively, our findings establish parthanatos as a clinically relevant regulatory axis in COAD and provide a novel framework for prognosis assessment and therapeutic targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsAdenocarcinomaHumansPrognosisGene Expression Regulation, NeoplasticCell ProliferationFemaleCell Line, TumorGene Expression ProfilingMale

Stichwörter der Autor:innen

SLC2A3colon adenocarcinomaimmune infiltrationmolecular subtypeparthanatos

Autor:innen und Institutionen

  • Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, 266071, Qingdao, China, qdu.edu.cn.
  • Department of Emergency, The Affiliated Hospital of Qingdao University, 266071, Qingdao, China, qdu.edu.cn.
  • Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, 266071, Qingdao, China, qdu.edu.cn.

ORCID-Profile: Kun Ju, Lei Luo

Zitieren

APA

Zhao, Z., Ju, K., Lv, J., Lu, Z., & Luo, L. (2026). Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/8383379

Vancouver

Zhao Z, Ju K, Lv J, Lu Z, Luo L. Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/8383379

BibTeX
@article{Zhao2026,
  author = {Zhao, Zhenyuan and Ju, Kun and Lv, Jiajun and Lu, Zidong and Luo, Lei},
  title = {Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma},
  journal = {Mediators of Inflammation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/mi/8383379}
}
Kostenlos starten →